About: http://data.cimple.eu/news-article/e6c8a0001820b311b88f395ed6dce938e02fa492e4a86e2ffde4665e

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/e6c8a0001820b311b88f395ed6dce938e02fa492e4a86e2ffde4665e Goto Sponge Distinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US pharmaceutical giant Johnson & Johnson said Tuesday it plans to provide 500 million doses of its vaccine for poor countries once results of clinical trials are announced by the end of January. It plans to sell the vaccine at cost price and will provide the doses to Gavi, the Vaccine Alliance, the group's scientific director Paul Stoffels told a virtual round table in Geneva. The vaccine is currently undergoing final-stage clinical trials involving 60,000 participants at more than 200 locations in the US and other countries. Results are expected in late January. J&J's Stoffels said the firm's Phase III trials -- which had to be interrupted briefly when one subject fell ill -- are now "in full swing", adding: "We target for results the month of January for efficacy and safety." AstraZeneca, a leading rival in the world scramble for a coronavirus vaccine, has also pledged to sell its candidate at cost -- around 2.50 euros ($2.80) per dose -- while Pfizer of the United States has targeted a top price of around $40. J&J had said in September that it hoped to win emergency authorisation to market its vaccine early next year. Unlike some rival vaccines that require storage at extremely low temperatures, J&J's can be kept at 2.0 degrees Centigrade (35.6 Fahrenheit). Speaking at the same conference, organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the head of Swiss lab Roche, Severin Schwan, said the at-cost model for vaccines could stymie innovation in the future. "It's a good model during a crisis, but I don't think it can be a standard for sustainable innovation in the long run," said Schwan, the IFPMA vice president. vog/nl/gd/adp
schema:headline	J&J readies 500 mn vaccine doses for poor countries
schema:mentions	Fahrenheit Geneva GAVI Celsius Hoffmann-La Roche Swing music Pharmaceutical industry Johnson & Johnson Switzerland AstraZeneca Pfizer Vaccine United States Severe acute respiratory syndrome coronavirus 2 Severin Schwan Paul Stoffels International Federation of Pharmaceutical Manufacturers & Associations Vog Adenosine diphosphate
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-12-08 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	79 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software